• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Report Describes the Segment of the Cell Therapy Market Aimed Specifically at Cancer Therapy

Posted on: Monday, 25 February 2008, 15:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c83800) has announced the addition of Cancer Cell Therapy Markets to their offering.

Traditionally, treatment of disease is carried out by small molecules that target specific cell types. In diseases such as cancer, the treatment is meant to kill cancer cells, leading to the removal or at least the inhibition of cancer cell proliferation. In other circumstances, a variety of therapeutic molecules have been utilized lead the disease cells to perform a specific function that they normally do not. These include small molecules, peptides, proteins, antibodies, anti-sense RNAs and ribozymes. In the case of cell therapy, as the name indicates, treatment is carried out with cells instead of small molecules. In cell therapy, cells are given to the patient as the therapeutic delivery system for a specific disease to achieve therapeutic benefit.

The purpose of this report is to describe the market segment of the cell therapy market aimed specifically at cancer therapy. Moreover, a review of cellular agents that are related to the chemical and cellular constituents of blood or other tissues for cancer care of the patient is addressed in this study. The two most important areas where such agents are used are in the hospital and the clinic. Emphasis is on those companies and products that are actively developing and marketing cell therapeutic agents and supplies for treating cancer patients.

Some Topics Covered:

-Biology of Cellular Therapy for Cancer: Different Cell Types Deployed and Disease Areas Addressed

-Components of the Hematopoietic System that can be Leveraged for Cancer Cellular Therapy

-Dendritic Cells

-Cytotoxic T Lymphocytes (CTLs)

-Natural Killer (NK) Cells

-Tumor Infiltrating Lymphocytes (TILs) also known as Lymphokine-activated Killers (LAKs)

-Hematopoietic Stem Cells (HSCs)

-Adult Stem Cell-based Therapies (ASCs)

-Stem Cell-based Cellular Therapies

-Effectiveness in Transplants of Peripheral Versus Bone Marrow Stem Cells

-What do HSCs do and what Factors are Involved in these Activities?

-Self-renewal of HSCs

-Differentiation of HSCs into Components of the Blood and Immune System

-Migration of HSCs Into and Out of Marrow and Tissues

-Leukemia and Lymphoma

-Inherited Blood Disorders

-HSC Rescue in Cancer Chemotherapy

-Graft-Versus-Tumor Treatment of Cancer

-Other Clinical Applications of HSCs

-What are the Challenges and Barriers to the Development of New and Improved Treatments Using HSCs?

-Current Status of Cellular Therapies for Cancer

-Tumor Antigens, Cancer Vaccines and Cellular Therapy

-Other Competing Antibody Technologies

-The Future of Cell Therapy Against Cancer

-Government Regulation of Cell Therapy Products

-Companies involved in Cancer Cell Therapy

-Company Profiles

Accentia Biopharmaceuticals, Inc.

Antigenics, Inc.

Biomira, Inc.

Biovest International, Inc.

Cell Genesys, Inc.

Dendreon Corp.

EMD Serono (Parent Company is Merck KGaA, Darmstadt, Germany)

Favrille, Inc.

Genitope Corporation

Genzyme Molecular Oncology

GlaxoSmithKline

IDM Pharma, Inc.

Juvaris BioTherapeutics, Inc.

Medarex, Inc.

Merck & Co., Inc.

Micromet, Inc.

Northwest Biotherapeutics, Inc.

Titan Pharmaceuticals, Inc.

Vical, Inc.

Cyclacel Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/reports/c83800

Source: Business Wire

More News in this Category